PITTSBURGH, Pa., Feb 3, 2026, 10:05 EST
- CMU team secures up to $26.7 million in federal funds for an at-home test that detects more than 30 Stage 1 cancers
- Learnvia, supported by Gates, is testing AI-driven math courseware at 38 colleges, with a Calculus I rollout planned for spring
- TALI teams up with Carnegie Mellon to kick off a six-month Emerging Leaders cohort featuring 29 professionals, set to graduate together in June
Carnegie Mellon University researchers are working on an at-home cancer screening test aimed at catching over 30 types of Stage 1 cancer. The project received funding up to $26.7 million from the Advanced Research Projects Agency for Health, the university announced on Feb. 2.
The funding is crucial because Stage 1—the earliest phase in many solid tumors—is often the toughest to detect but the easiest to treat. According to the university, ARPA-H, a U.S. health-research agency, aims to support projects that conventional grants or private investors typically overlook or delay.
Carnegie Mellon-affiliated groups are now expanding their focus beyond just lab research. A new nonprofit connected to the university has begun testing AI courseware in college math classes. At the same time, a Pittsburgh leadership institute and the university launched a new cohort to develop a pipeline of Black leaders and their allies.
The proposed cancer screening involves several steps done at home: first, the patient swallows a bioengineered pill packed with tumor sensors. Next, they complete a urine test using a compact device that detects cancer-related signals and pinpoints where in the body the cancer originated. According to the university, results are then transmitted through a smartphone to a healthcare provider.
Rebecca Taylor, the project’s principal investigator, said the goal is an annual at-home screening for “a range of small tumor types,” though she acknowledged that “solid tumors at Stage 1 are super hard to detect.” She added that the research kicked off in October 2025.
Cost is a constraint, not an afterthought. Taylor noted the team is collaborating with UPMC Hillman Cancer Center on community surveys. ARPA-H aims for a $100 selling price, which she described as “a big challenge.”
ARPA-H’s POSEIDON program currently backs this project, alongside other teams from Grafton Biosciences, Owlstone Medical, and SRI International, per the agency’s website. Carnegie Mellon’s group counts Ginkgo Bioworks as a commercial partner, the site notes.
Learnvia is rolling out interactive lessons and AI tutoring tools targeting “gateway” courses—those large intro classes that can stall students’ progress if they don’t pass. The Gates Foundation has backed the initiative with a $55 million donation over three years. This spring, 38 partner schools will test a Calculus I pilot, 90.5 WESA reported.
Norman Bier, executive director at Learnvia, told WESA that students dropping gateway courses often face “tremendous personal cost.” He emphasized the issue extends beyond a single campus. Bier added that the tools aim to “amplify great teaching,” not to replace instructors.
On Jan. 29, The Chronicle of Higher Education reported that Learnvia’s courseware features video lessons, homework, quizzes, and an AI tutor that professors can customize or bypass. Patrick Methvin, the foundation’s director of postsecondary success, told the Chronicle the goal was to create more than just a tool—it’s about building “an organization” that offers professional development as well. Source
Separately, The Advanced Leadership Institute (TALI) kicked off its 2026 programming year with the fifth cohort of its Emerging Leaders Program. The initiative runs through Carnegie Mellon’s Tepper School of Business and partners with the University of Pittsburgh, Robert Morris University, and Duquesne University. The program introduced a new six-month hybrid format covering negotiation, executive presence, and more. The 29 participants started on Jan. 30, with graduation slated for June. Evan Frazier, who helped launch the program five years ago, said it aims to “cultivat[e] the next generation of senior leaders.” Carnegie Mellon’s Isabelle Bajeux-Besnainou added the school is “excited” to equip participants with the tools they need to succeed. Source
None of this is a sure thing yet. The cancer test remains under development, and early screening tools frequently grapple with issues around accuracy, follow-up care, and whether users trust results from consumer gadgets. Meanwhile, AI courseware encounters doubt from faculty and students who see “smart” systems as a potential source of extra hassle.
The timelines remain uneven. Learnvia’s initial batch hits classrooms this spring, while TALI’s group aims to wrap up by June. Meanwhile, Taylor’s team is still developing a cancer screen, working under tough cost and usability constraints.
